Clinical Study | Office of Clinical Research

Study Of Amantadine Hcl Extended Release Capsules For The Treatment Of Levodopa Induced Dyskinesia

Posted Date: May 15, 2019

Investigator: Alberto Espay
Type of Study: Drug

Amantadine, in an immediate-release (IR) formulation, is approved by the FDA for the treatment of Parkinson?s disease (PD). Neurologists sometimes also use amantadine to treat levodopa-induced dyskinesia (LID) in patients with Parkinson?s disease, or involuntary movements involving the head, body,

Criteria:

You Are Being Asked To Participate In This Study Because You Have Parkinson?S Disease And Have Levod

Keywords:

Adamas Amt-Ads-Pd302, Levodopa Induced Dys, Amantadine Extended , Espay, Parkinson's Disease

For More Information:

Katie Krier
(513) 558-0169
katie.krier@uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List